|Year : 2021 | Volume
| Issue : 2 | Page : 43-44
Post-COVISHIELD™ vaccination symptoms among health-care workers – A multicentric survey
Mahima Lakhanpal, Ritesh Kumar, Debapriya Sarkar
Department of Anesthesia, Santosh Deemed to be University, Santosh Medical College Hospital, Ghaziabad, Uttar Pradesh, India
|Date of Web Publication||6-Dec-2021|
Department of Anesthesia, Santosh Deemed to be University, Santosh Medical College Hospital, Ghaziabad, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Lakhanpal M, Kumar R, Sarkar D. Post-COVISHIELD™ vaccination symptoms among health-care workers – A multicentric survey. Santosh Univ J Health Sci 2021;7:43-4
|How to cite this URL:|
Lakhanpal M, Kumar R, Sarkar D. Post-COVISHIELD™ vaccination symptoms among health-care workers – A multicentric survey. Santosh Univ J Health Sci [serial online] 2021 [cited 2022 May 18];7:43-4. Available from: http://www.sujhs.org/text.asp?2021/7/2/43/331789
| Introduction|| |
Amid global crisis, due to COVID-19, the human survival and struggle story is one of a kind. With the successful effort of world scientists working together, finally, a vaccine has been made. India in this crisis times proved its worth in fighting the pandemic and along with many other countries throughout the world finally approved vaccines on emergency approval to be administered. In India, COVISHIELD™ (manufactured by Serum Institute of India Pvt Ltd), a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike (S) glycoprotein, and COVAXINTM (Bharat Biotech International Limited), a whole-virion inactivated SARS-CoV-2 antigen, have been given restricted use license for emergency and can be used for active immunization of individuals aged 18 years and older for the prevention of coronavirus disease (COVID-19).,, The immunization started on a large scale on January 16, 2021, in multicenter all over India with the priority of health-care workers (HCWs) to be vaccinated initially. We conducted a multicentric survey in centers with COVISHIELD™ vaccination and looked for common side effects post vaccination among HCWs and the overall experience.
| Materials and Methods|| |
A detailed questionnaire was prepared and 332 responses were noted through online forms. Obtained data were calculated in a spreadsheet in MS Excel.
| Results|| |
A total of 332 HCWs including doctors from various specialty and assistant staff responses were noted. Out of 332 responses from HCW, 158 were female and 174 male. Previously, COVID reverse transcriptase–polymerase chain reaction was positive in 58 (17%) people only. The most common symptoms post COVISHIELD™ vaccination among recipients was pain at the vaccination site (54.21%) followed by generalized malaise which was present in 36.4% HCW. About 34.6% of recipients had myalgia, whereas 31.32% had fever. Other symptoms were chills, headache, rigors, swelling at the vaccination site, vomiting, and dizziness. Eight-three (25%) HCWs had no symptoms at all. Among 332 HCWs, 20 (6.02%) recipients took tablet paracetamol 650 mg prophylactically before vaccination and 83 (25%) took tab paracetamol post vaccination, whereas 229 (69%) people choose not to take any medication at all.
| Discussion|| |
Post COVISHIELD™ vaccination, there was a constellation of many symptoms most common being pain at the vaccination site followed by malaise, myalgia, fever, chills, and headache. The majority of vaccine recipients' had mixed symptoms. The symptoms mostly developed almost 8 to 12 h after vaccine administration. The symptoms' onset or severity was not associated with gender or age among the sample. Furthermore, the severity was not related to consumption of analgesic (tablet paracetamol) prophylactically or postvaccination in comparison to those who choose not to take any medication. Previously, COVID RT-PCR-positive status was present in a very small percentage and also severity or onset was similar with the HCW who was never positive. No severe reaction which required hospitalization was noted in any of the HCW. If we go through the symtoms of post-COVISHIELD vaccination, they are actually common symptoms that can be encountered after administration of any other vaccine. Almost 91.3% of HCWs were satisfied with the experience.
The decision of administration of a vaccine to the HCW first was actually to provide a protective shield to the frontline warriors, but now, this decision has an added boon. The HCW will be able to guide and prevent panic among common men by assuring them that this is a normal response to the vaccine.
| Conclusion|| |
The fight against the virus is still going on with vaccines on our side let's hope things will be easy for us. Furthermore, larger groups and data are needed to study the postvaccination symptoms which are ultimately necessary for the improvement of vaccine or recipients compliance.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Thiagarajan K. COVID-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ 2021;372:n196.